The latest price target for Amphastar Pharma (NASDAQ:AMPH) was reported by Piper Sandler on February 4, 2025. The analyst firm set a price target for $36.00 expecting AMPH to rise to within 12 months (a possible 15.09% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Amphastar Pharma (NASDAQ:AMPH) was provided by Piper Sandler, and Amphastar Pharma downgraded their neutral rating.

There is no last upgrade for Amphastar Pharma

The last downgrade for Amphastar Pharmaceuticals Inc happened on February 4, 2025 when Piper Sandler changed their price target from $66 to $36 for Amphastar Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amphastar Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amphastar Pharma was filed on February 4, 2025 so you should expect the next rating to be made available sometime around February 4, 2026.

While ratings are subjective and will change, the latest Amphastar Pharma (AMPH) rating was a downgraded with a price target of $66.00 to $36.00. The current price Amphastar Pharma (AMPH) is trading at is $31.28, which is out of the analyst’s predicted range.